DiaMedica Therapeutics Inc. Common Stock (DMAC)
Stock · NASDAQ · Health Care
$7.57as of 10/16/2026
Price chart
Active signals
DMAC Signal Track Record
How signals performed across all stocks →What DMAC's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 47 | +4.7% | 64% | September 16, 2026 |
| Bollinger Band Breakout | 24 | +2.1% | 54% | September 21, 2026 |
| Bollinger Band Breakdown | 22 | +4.2% | 59% | August 31, 2026 |
| 200-Day Moving Average TouchActive now | 16 | -2.3% | 44% | June 29, 2026 |
| Any 20-session window (baseline) | +2.0% | 54% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About DMAC
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal g…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 35
- Website
- www.diamedica.com/
Fundamentals
- 1-day range
- $8.02$8.61
- Market cap
- $364.79M
- P/E (trailing)
- —
- P/E (forward)
- -10.19
- EPS (trailing)
- $-0.72
- Dividend yield
- —
- Beta
- 0.96
- Avg. volume
- 181.8K
- Dividend pay date
- November 15, 2018
How DiaMedica Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2018 annual results
Source: 10-K filed Mar 19, 2019 · via SEC EDGAR / Finnhub
Forecasts
4 analyst ratings
DiaMedica Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- DMACDiaMedica Therapeutics Inc. Common Stock$7.57▼ 5.85%Market cap $364.79MP/E —$5.25$10.42
- NATRNature's Sunshine Products Inc. Common Stock$12.64▲ 0.00%Market cap $357.68MP/E 12.66$12.8$28.14
- PRLDPrelude Therapeutics Incorporated Common Stock$3.26▼ 1.81%Market cap $372.74MP/E —$1.16$6.83
- ZNTLZentalis Pharmaceuticals Inc. Common Stock$2.13▼ 4.91%Market cap $355.93MP/E —$1.21$6.95
- UPBUpstream Bio Inc. Common Stock$2.76▼ 18.10%Market cap $373.87MP/E —$3.29$33.68
- LYELLyell Immunopharma Inc. Common Stock$8.12▼ 0.85%Market cap $348.21MP/E —$7.2$45
- RCKTRocket Pharmaceuticals Inc. Common Stock$2.18▼ 7.63%Market cap $386.55MP/E —$2.42$5.45
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| DMAC DiaMedica Therapeutics Inc. Common Stock | $364.79M | — | $7.57 | ▼ 5.85% | $5.25$10.42 |
| NATR Nature's Sunshine Products Inc. Common Stock | $357.68M | 12.66 | $12.64 | ▲ 0.00% | $12.8$28.14 |
| PRLD Prelude Therapeutics Incorporated Common Stock | $372.74M | — | $3.26 | ▼ 1.81% | $1.16$6.83 |
| ZNTL Zentalis Pharmaceuticals Inc. Common Stock | $355.93M | — | $2.13 | ▼ 4.91% | $1.21$6.95 |
| UPB Upstream Bio Inc. Common Stock | $373.87M | — | $2.76 | ▼ 18.10% | $3.29$33.68 |
| LYEL Lyell Immunopharma Inc. Common Stock | $348.21M | — | $8.12 | ▼ 0.85% | $7.2$45 |
| RCKT Rocket Pharmaceuticals Inc. Common Stock | $386.55M | — | $2.18 | ▼ 7.63% | $2.42$5.45 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Dietrich John Pauls · August 10, 2026 · Grant60.2K
- Julie Krop · June 1, 2026 · Grant67.5K
- Charles Pauling Semba · June 1, 2026 · Grant40.4K
- Dietrich John Pauls · June 1, 2026 · Grant380.0K
- James T. Parsons · June 1, 2026 · Grant51.2K
- Randall Michael Giuffre · June 1, 2026 · Grant40.4K
- Kellen Scott · June 1, 2026 · Grant162.0K
- Lewis Tanya · June 1, 2026 · Grant40.4K
- O'Connor Daniel J. · June 1, 2026 · Grant40.4K
- Richard Kuntz · June 1, 2026 · Grant40.4K
Institutional Ownership
March 31, 2026
- Total shares held
- 11.26M
- Total value held
- $75.63M
- Institutional holders
- 93
- Unknown2.02M
- Unknown1.86M
- Unknown935.6K
- Unknown875.0K
- Unknown780.5K
- Unknown644.2K
- Unknown455.0K
- Unknown382.3K
- Unknown338.5K
- Unknown333.5K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
DiaMedica Shares Early Phase 2 Data for DM199 in Fetal Growth Restriction
DiaMedica Therapeutics is highlighting early Phase 2 results for its lead candidate, DM199, which targets fetal growth restriction. The company is using a webinar with key opinion leaders to discuss these findings, signaling a focus on advancing its clinical narrative. This update provides new information on the drug's potential efficacy as it moves through its development stages.
DiaMedica Shares Early Phase 2 Data for DM199 in Fetal Growth Restriction. DiaMedica Therapeutics is highlighting early Phase 2 results for its lead candidate, DM199, which targets fetal growth restriction. The company is using a webinar with key opinion leaders to discuss these findings, signaling a focus on advancing its clinical narrative. This update provides new information on the drug's potential efficacy as it moves through its development stages.